Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.

Targeted Inhibition of CYP11A1 in Prostate CancerIn this single-arm, multicenter, combined phase 1 and phase 2 study, patients with metastatic prostate adenocarcinoma with progression on prior androgen receptor pathway inhibitors and taxane-based chemotherapy were treated with ODM-208. A decrease in prostate-specific antigen levels of 50% or more occurred in 16/42 (38.1%) and 24/45 (53.3%) in phase 1 and 2 respectively. Responses mainly occurred in patients with androgen receptor mutations. Adrenal insufficiency was the dose-limiting toxicity.

NEJM evidence. 2023 Dec 26 [Epub]

Karim Fizazi, Alice Bernard-Tessier, Guilhem Roubaud, Tapio Utriainen, Philippe Barthélémy, Aude Fléchon, Johannes van der Voet, Gwenaëlle Gravis, Raffaele Ratta, Robert Jones, Omi Parikh, Minna Tanner, Emmanuel S Antonarakis, Capucine Baldini, Niamh Peters, Chris Garratt, Tarja Ikonen, Pasi Pohjanjousi, Heikki Joensuu, Natalie Cook

Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France., Medical Oncology, Institut Bergonié, Bordeaux, France., Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland., Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Medical Oncology, Centre Léon Bérard, Lyon, France., Radiotherapy, The James Cook University Hospital, Middlesbrough, United Kingdom., Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Medical Oncology, Hôpital Foch, Suresnes, France., Cardiff University and Velindre University National Health Service Trust, Cardiff, United Kingdom., Oncology, Royal Preston Hospital-Lancashire Teaching Hospitals National Health Service Foundation Trust, Preston, United Kingdom., R&D, Tampere University Hospital, Tampere, Finland., Department of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis., Drug Development Department, Université Paris-Saclay, Gustave Roussy, Villejuif, France., University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom., Orion Corporation, Orion Pharma, Espoo, Finland.